-
REVIEW: Emerging roles in cancer progression and treatment
-
the placental C5a/C5aR pathway contributed to the development of pre eclampsia by regulating placental trophoblasts dysfunctions.
-
Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host major complement components C3, C4, and C5.
-
Furthermore, Apigenin reduced the proliferation of human NPC cells triggered by C5a through negative regulation of C5aR/PCAF/STAT3 axis. These might provide a new insight into the function of Apigenin in cancer treatment, and also provide a potential strategy for treating human NPC through inhibition of C5aR expression on cancer cells
-
Study identified that peripheral mRNA expression levels of two complement genes (C5, SERPING1) made unique contributions to the variance in superior frontal cortical thickness. Vertex-wise maps of the association between gene expression levels and thickness across the cortex suggested that this relationship was especially strong with SERPING1 in the superior frontal region.
-
these data demonstrate that Mesenchymal Stem Cells inhibit the activation of pathogenic C5 via up-regulation of FH, which improves our understanding of the immunomodulatory mechanisms of MSCs in the treatment of lupus nephritis.
-
recombinant C5a potentiated TNFalpha-induced NF-kappaB activation in renal tubular epithelial cells
-
tumoral C5a is an independent adverse prognostic biomarker for clinical outcome of Clear Cell Renal Cell Carcinoma patients after nephectomy.
-
C5a synergises with P. aeruginosa LPS in both PD-L1 expression and the production of IL-10 and TGF-beta.
-
these results not only confirm the critical role of C5b-9 in complement-mediated hemolysis and but also highlight the critical role of C5b-9 in inflammasome activation.
-
Mean cerebrospinal fluid C5 levels increased in patients with depression and schizophrenia.
-
elevated in the cerebrospinal fluid of preterm newborns
-
Up-regulation of granulocyte and monocyte CD11b during plasma separation was C5-dependent.
-
This study provides the preclinical rationale for the combined blockade of PD-1/PD-L1 and C5a to restore antitumor immune responses, inhibit tumor cell growth, and improve outcomes of patients with lung cancer
-
Diagnosis and therapeutic management of neonatal hemochromatosis cannot only be based on C5b9 expression in liver samples as it is not specific of this disease.
-
C5a-C5aR enriched clear cell renal cell carcinoma patients significantly had a poorer overall survival and recurrence free survival after nephrectomy.
-
The complement activation factors Bb, C3a, C5a, and MAC were increased significantly in early-onset severe pre-eclampsia (EOSPE) (all P<.01) and late-onset severe pre-eclampsia (LOSPE). (P value: .027, <.001, .001, and <.001, respectively) compared with E/L-control. C1q and C4d were increased significantly in LOSPE (P value: .003 and .014, respectively) compared with L-control.
-
C5a/C5aR pathway promotes gastric cancer pathogenesis by suppressing p21/p-p21 expression via activation of PI3K/AKT signaling.
-
this study shows that C5 acts in the control of serum triglycerides and cholesterol, liver cholesterol deposition, liver homeostasis and C5 promotes a pro-inflammatory liver environment in our mouse model of alcoholic liver disease
-
a library of 61 peptides based on the C-terminus of C5a was assayed for the ability to selectively modulate C5aR2 function.
